Aimmune Therapeutics, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

organization

SEC Insider

$2.63B

513 transactions

Summary

Aimmune Therapeutics, Inc. is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $2.22BSales: $44.8M30 insiders

Date	Insider	Type	Value
2020-10-13	ADELMAN DANIEL C MD(Chief Medical Officer)	D	$3.1M
2020-10-13	ENRIGHT PATRICK G	D	$2.3M
2020-10-13	ENRIGHT PATRICK G	D	$1.5M
2020-10-13	ADELMAN DANIEL C MD(Chief Medical Officer)	D	$1.0M
2020-10-13	ADELMAN DANIEL C MD(Chief Medical Officer)	D	$771K
2020-10-13	ADELMAN DANIEL C MD(Chief Medical Officer)	D	$768K
2020-10-13	ADELMAN DANIEL C MD(Chief Medical Officer)	D	$561K
2020-10-13	FALBERG KATHRYN E	D	$377K
2020-10-13	ENRIGHT PATRICK G	D	$377K
2020-10-13	FALBERG KATHRYN E	D	$284K
2020-10-13	ENRIGHT PATRICK G	D	$284K
2020-10-13	FALBERG KATHRYN E	D	$270K
2020-10-13	ENRIGHT PATRICK G	D	$270K
2020-10-13	FALBERG KATHRYN E	D	$268K
2020-10-13	ENRIGHT PATRICK G	D	$268K
2020-10-13	FALBERG KATHRYN E	D	$167K
2020-10-13	ENRIGHT PATRICK G	D	$167K
2020-10-13	ADELMAN DANIEL C MD(Chief Medical Officer)	D	$24K
2020-10-13	FALBERG KATHRYN E	D	$13K
2020-10-13	ENRIGHT PATRICK G	D	$13K

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

Aimmune Therapeutics, Inc. — Contributions, Lobbying & Contracts | Poliscope